Related Experiment Videos

Efficacy of ceftriaxone and gentamicin in an abscess model

Insights

Ceftriaxone effectively treated abscesses caused by Klebsiella pneumoniae in rats, especially when given early. Gentamicin showed limited efficacy in this foreign body abscess model.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Abscesses are localized pus collections often caused by bacterial infections.
  • Foreign body presence can complicate infection and treatment.
  • Klebsiella pneumoniae is a common pathogen in healthcare-associated infections.

Purpose of the Study:

  • To evaluate the in vivo efficacy of ceftriaxone and gentamicin against Klebsiella pneumoniae in a rat foreign body abscess model.
  • To compare the therapeutic effects of monotherapy versus combination therapy.
  • To assess the pharmacokinetic profiles of both antibiotics within abscess fluid.

Main Methods:

  • A rat subcutaneous abscess model was created using a dialysis tube contaminated with Klebsiella pneumoniae.
  • Animals received ceftriaxone, gentamicin, or combination therapy for four days, initiating treatment immediately or 48 hours post-implantation.
  • Antibiotic concentrations in abscess fluid and blood were measured.

Main Results:

  • Ceftriaxone significantly inhibited abscess formation when administered early; gentamicin showed no benefit.
  • Both antibiotics had longer persistence in abscess fluid compared to blood.
  • Combination therapy offered a slight advantage over ceftriaxone monotherapy.
  • Delayed treatment (48 hours) reduced ceftriaxone efficacy, while gentamicin remained ineffective.

Conclusions:

  • Ceftriaxone demonstrates superior therapeutic efficacy over gentamicin for Klebsiella pneumoniae-induced foreign body abscesses in rats.
  • Early administration of ceftriaxone is crucial for optimal treatment outcomes.
  • Low oxygen tension in abscesses may contribute to gentamicin's reduced bactericidal activity.
  • Ceftriaxone is a potentially more suitable agent for treating closed-space infections caused by susceptible pathogens.

Related Concept Videos